Month: January 2026

Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue’s U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company’s enteral platform. “Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships...

Enterprise-grade AI reduces operational cost, accelerates customer resolution, and establishes a scalable automation blueprint New York, Jan. 21, 2026 (GLOBE NEWSWIRE) — Global AI Inc. (OTC: GLAI), a leader in enterprise artificial intelligence (AI), agentic products and solutions, today announced that a leading insurance provider and asset management groups in Europe, has engaged Global AI to implement its agentic artificial intelligence platform to modernize and automate a high-volume, compliance-critical insurance workflow. The initiative replaces a fully manual, document-intensive back-office process with a governed, agentic AI validation layer that is fully integrated into the insurer’s existing customer channels and core back-office systems. The deployment has been executed in line with the insurer’s enterprise security,...

WALTHAM, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension”, “Nano”, or the “Company”), a leader in digital manufacturing solutions, today announced a preliminary update on its fourth quarter 2025 revenue performance and provided updates on key business initiatives, including its strategic alternative review and redomestication processes. Preliminary Fourth Quarter 2025 Revenue Outperformance Based on preliminary, unaudited results, the Company expects fourth quarter 2025 revenue to be in the range of $35.0 million to $35.5 million, exceeding the revenue guidance range of $31.5 million to $33.5 million provided on its November 19, 2025 earnings call. This performance highlights the strength of the Company’s differentiated portfolio as demand increases for advanced digital manufacturing...

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.   The 7th RNAi-Based Therapeutics Summit is the industry’s premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, and oncological diseases. Silexion is developing SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes – the most common oncogenic driver in human cancers. SIL204 is planned to enter a Phase 2/3 clinical study program in locally advanced pancreatic cancer in mid 2026. Silexion management...

LAS VEGAS and FAIRFIELD, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures”), a diversified holding company, today announced that its Flooring Liquidators, Inc. (“Flooring Liquidators”) subsidiary has deployed artificial intelligence as a core operational intelligence system, transforming raw transactional data into predictive business insights that are reshaping inventory placement, delivery efficiency, and in-store availability. Rather than using AI as a back-office tool, Flooring Liquidators has embedded intelligence directly into day-to-day operations. AI-driven demand forecasting now translates real-time sales, inventory movement, and regional buying patterns into forward-looking decisions, enabling the company to position the right products closer to customers before demand...

BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) — NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group’s tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong’s first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF’s inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As Senior Counsel, Mr. Chu will lead the structuring and issuance of NIVF’s first tranche of tokenized bonds, with subscriptions of up to USD 30 million,...

– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the meeting, the FDA raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo. The primary endpoint of the Phase 3 studies will be the change in average daily pain score (ADPS) from baseline to Week 12. “Our End-of-Phase 2...

IRVINE, California, Jan. 21, 2026 (GLOBE NEWSWIRE) — Linkhome Holdings Inc. (“Linkhome” or the “Company”), an AI-powered real estate technology company, today announced that its principal shareholders have entered into agreements with the Company to extend their lock-up restrictions until July 24, 2026. This extension follows the original six-month lock-up period established in connection with the Company’s initial public offering. The principal shareholders participating in the lock-up extension collectively hold approximately 8.07 million shares of the Company’s issued and outstanding common stock. Pursuant to the terms of the lock-up agreements, these shareholders are prohibited from, directly or indirectly, selling, transferring, or otherwise disposing of the Company’s common stock, or any securities exercisable for, exchangeable...

Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026                   Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today announced its expected corporate milestones for the first quarter of 2026. “We expect to achieve three important goals during Q1 2026 to drive value for patients with osteoporosis and hypoparathyroidism. We would like to thank the investigators from around...

Next-Generation Functional Beverage Platform Carrying Popular Brands Bucked Up and Ballislife Warwick, NY, Jan. 21, 2026 (GLOBE NEWSWIRE) — Ozop Energy Solutions, Inc. (OZSCD), proudly announces that it has entered into an agreement to acquire Varon Corp, a next-generation functional beverage platform built for culture-driven scale, rapid commercialization, and capital-efficient growth across North America. “This acquisition marks a clear turning point for Ozop,” said Brian Conway, Chief Executive Officer of Ozop Energy Solutions, Inc. “Varon is a growing, revenue-generating beverage company with established brands, embedded cultural distribution, and an experienced management team. By combining Ozop’s public-market structure with Varon’s operating engine, we are repositioning the Company around scalable revenue, disciplined execution,...